Thursday, January 27, 2022
News
NEWS HOME
»
PRN INDIA
RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results
  SocialTwist Tell-a-Friend  
   

RedHill Accelerates its Two Advanced COVID-19 Pill Clinical Programs in Light of their Potential Against Omicron

Acting independently of spike protein mutation, opaganib and RHB-107's unique host-targeted mechanisms of action hold potential versus Omicron and other variants

-- Phase 2/3 study sub-population analysis demonstrated a 62% reduction in mortality in moderately severe hospitalized patients; Data packages submitted in the U.S., EU (EMA has provided expedited evaluation process timelines), UK and other territories, ahead of regulatory advice

-- Top-line data from Part A of the COVID-19 Phase 2/3 study of RHB-107 (upamostat) in non-hospitalized symptomatic COVID-19 patients in the U.S. and South Africa expected in Q1/2022

-- Second consecutive quarter of record net revenues with $21.6 million for Q3/2021 and an increase in gross margin and steep reduction in operating and net loss; Cash balance[1] of $51.5 million as of September 30, 2021

-- Strategic investment in RedHill by South Korea's Kukbo Co. of up to $10 million as well as a $15.5 million underwritten public offering in November

-- Another record quarter for Talicia ® revenues, with new prescription volume up 15%, reflecting 117% growth vs. Q3/2020; Movantik ® continues to rise with an increase in quarterly new prescriptions of 1.1%

--  Continued prescription volume growth seen into the fourth quarter to date for both Talicia and Movantik, with coverage increase on both commercial and government formularies  

-- Management to host webcast today, at 8:30 a.m. EST

TEL AVIV, Israel and RALEIGH, N.C., Nov. 30, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its financial results and operational highlights for the third quarter ended September 30, 2021.

RedHill Biopharma Logo

Dror Ben-Asher, RedHill's Chief Executive Officer, said: "Our U.S. commercial business continues to drive growth, delivering a second consecutive quarterly net revenue record of $21.6 million despite the continuously challenging pandemic environment. Talicia generated another record quarter with 15% growth in new prescriptions, while Movantik continues to perform adding a 1.1% increase to new prescriptions. Both products are also continuing to make strides in gaining both commercial and government formulary coverage. In addition, gross margin increased from 51% in the second quarter to 57% in the third quarter. The Company has successfully attracted a strategic investment from South Korea's Kukbo and continues to demonstrate responsible financial discipline across the entire business as we strive to achieve our long-term growth aims."  

Mr. Ben-Asher added: "Given the recent emergence of the heavily mutated Omicron variant as well as likely emergence of other variants over time, the importance of drug candidates that act independently of the viral spike protein is growing. This makes both opaganib and RHB-107's host-targeted mechanism of action, and expected maintenance of effect against new variants, increasingly more relevant in the battle against COVID-19. This quarter saw significant focus on our opaganib Phase 2/3 COVID-19 study. The initial top-line results demanded further investigation and our rigorous post-hoc analysis provided much greater clarity into the potential of novel, orally-administered opaganib in the underserved hospitalized moderately severe patient group. This is a group of patients for which no novel therapeutic pill has shown a benefit until opaganib, which demonstrated a 62% reduction in mortality, improved return to room air and earlier hospital discharge for opaganib-treated patients. The results of this analysis, in a group of more than half the total study population, were consistent with what we had seen in our Phase 2 study and compassionate use experience. Despite being a post-hoc analysis, the consistency across multiple endpoints and territories provides us with a high degree of confidence in the results showing opaganib's effect in this patient population. This analysis also shed light on key issues of the COVID-19 disease severity classification, suggesting that FiO2 might be an improved method for classifying disease severity and predictor of treatment outcome. We have now provided regulators in various countries with all the necessary data to facilitate discussions on the next steps and we continue to provide the data to regulators in additional countries."

"In parallel, we continue to progress our Phase 2/3 study in the U.S. and South Africa with our other novel, once-daily, oral COVID-19 antiviral drug candidate, RHB-107, which has now completed enrollment for Part A of the study, with top-line results expected in the first quarter of 2022. Our Phase 3 study of RHB-204 in pulmonary nontuberculous mycobacteria (NTM) disease continues to enroll patients in the U.S. and progress with Phase 3-stage RHB-104 for Crohn's disease is expected to speed up thanks to recent, much-awaited, potential progress in Mycobacterium avium subspecies paratuberculosis (MAP) detection research[2]."

"With a steep reduction in quarterly operating and net loss and continued commercial business growth, leading to a potential commercial operational breakeven before the end of the year, coupled with advanced, exciting and timely R&D pipeline progress, I believe RedHill is well positioned for short, medium and long-term success."

Financial highlights for the quarter ended September 30, 2021[3]

Net Revenues  were $21.6 million for the third quarter of 2021, as compared with $21.5 million for the second quarter of 2021. The increase is attributable to an increase in sales of Talicia and Movantik, partially offset by an increase in gross-to-net deductions, mainly commercial rebates and Medicare discounts.

Gross Profit was $12.4 million for the third quarter of 2021, compared to $10.9 million for the second quarter of 2021 - an increase of 14%. Gross margin increased from 51% in the second quarter of 2021 to 57% in the third quarter of 2021. The increase in gross profit was mainly attributable to a reversal of inventory write-off recognized in the third quarter of 2021 following the FDA approval of an extension to Talicia stock expiration date.

Research and Development Expenses  were $5.8 million for the third quarter of 2021, a decrease of $4.5 million, a 44% reduction compared to the second quarter of 2021, mainly attributable to the completion of our global COVID-19 Phase 2/3 study with opaganib.

Selling, Marketing and General and Administrative Expenses  were $24 million for the third quarter of 2021, a decrease of $1.5 million compared to the second quarter of 2021. The decrease was mainly attributable to expenses related to share-based compensation in the previous quarter.

Operating Loss and Net Loss  were $17.4 million and $21.4 million, respectively, for the third quarter of 2021 compared to $24.9 million and $29.1 million, respectively, in the second quarter of 2021. The decrease was mainly attributable to the Talicia inventory expiration date extension, completion of our opaganib Phase 2/3 COVID-19 study and a decrease in expenses related to share-based compensation, as detailed above.

Net Cash Used in Operating Activities  was  $19 million for the third quarter of 2021, similar to the second quarter of 2021.

Net Cash Used in Financing Activities  was  $1 million for the third quarter of 2021, comprised primarily of payables with respect to the Movantik acquisition, partially offset by proceeds from utilization of ATM and from exercise of options.

Cash Balance1 as of September 30, 2021, was $51.5 million.

Additional Financial Highlights

In November 2021, the Company announced that it had entered into a strategic agreement with Kukbo Co. Ltd., a South Korean corporation, for the sale of RedHill's American Depositary Shares (ADSs) in a private placement of up to $10 million, of which the first tranche of $5 million has been paid. As part of the agreement, the Company granted Kukbo a six month right of first offer for a license with respect to one or more of opaganib, RHB-107 (upamostat) and Talicia ® for South Korea and other Asian territories.

In addition, this month, the Company completed an underwritten public offering of approximately 4.7 million ADSs for gross proceeds of approximately $15.5 million, led by Cantor Fitzgerald.

Commercial Highlights

Movantik ® (naloxegol)[4]

The Company's focus on driving Movantik performance and strengthening of market share continues unabated, resulting in another quarter of new prescription growth, increasing by 1.1% compared to the previous quarter.

The Company has achieved significant market access successes with U.S. major payors, continuing to increase the levels of payor coverage.

In July, one of America's largest payors, serving many Blue Cross and Blue Shield Plans and more than 30 million members, had added Movantik as a preferred brand with no restrictions to its Commercial NetResults "A" series formularies and as a preferred brand on its other commercial formularies starting July 1, 2021. In April, Movantik was also included on the Part D formulary of another major payor with no restrictions. Almost 9 out of 10 U.S. commercial lives are now covered, and we continue to work toward additional formulary coverage for the remaining patients.

In September 2021 RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals LP and Nektar Therapeutics entered into a settlement and license agreement with Aurobindo Pharma USA, Inc. resolving their patent litigation in the U.S. in response to Aurobindo's Abbreviated New Drug Application (ANDA) seeking approval by the FDA to market a generic version of Movantik. This follows the previously announced resolution of the Apotex litigation and brings to a close all presently pending Movantik patent litigation brought pursuant to The Drug Price Competition and Patent Term Restoration Act (the Hatch-Waxman Act). The earliest licensed entry date of any generic naloxegol in the U.S. is October 1, 2030.

Talicia ® (omeprazole magnesium, amoxicillin and rifabutin)[5]
Talicia achieved another record quarter, delivering a 15% increase in new prescriptions, compared to the previous quarter, reflecting 117% growth of Talicia as compared to Q3/2020.

In October, Medi-Cal - California's Medicaid Health Care program covering two million beneficiaries - had added Talicia to its Contract Drug List (CDL) for H. pylori treatment, with no prior authorization required. This coverage is expected to expand to 14 million beneficiaries on January 1, 2022. During the same month, a new U.S. Patent covering Talicia was granted. This patent reinforces the protection for Talicia through 2034, and the Company has listed this patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.

In July, the Company significantly expanded commercial coverage for Talicia, announcing that OptumRx, part of the UnitedHealth Group, a leader in healthcare coverage, partnered with more than 1.3 million healthcare professionals and 6,500 hospitals, had added Talicia to its Commercial Formulary as an unrestricted brand for H. pylori treatment, effective July 1, 2021. This agreement expanded access to Talicia to 26 million additional Americans and increased overall patient access to Talicia to greater than 8 out of 10 covered U.S. Commercial lives.

Aemcolo ® (rifamycin)[6]
The Company has maintained promotion of Aemcolo in the third quarter of 2021 supporting the initial momentum that Aemcolo was generating pre-COVID-19 travel restrictions. RedHill and Cosmo Pharmaceuticals N.V are currently in discussions with respect to the amendment of the Aemcolo License Agreement.

R&D Highlights

COVID-19 Program: Opaganib (ABC294640)[7]  
In September 2021, the Company announced top-line results from the global 475-patient Phase 2/3 study in hospitalized patients with severe COVID-19 pneumonia (NCT04467840). Whilst results showed consistent trends in favor of the opaganib arm, the study endpoints did not achieve statistical significance.

A post-hoc analysis of data from 251 study participants requiring a Fraction of inspired Oxygen (FiO2) up to 60% at baseline (54% of the study participants), was subsequently reported in October 2021, demonstrating that treatment with oral opaganib resulted in a 62% reduction in mortality as well as improved outcomes in time to room air and median time to hospital discharge, in this large group of hospitalized, moderately severe COVID-19 patients.

The results provide a strong rationale for opaganib's potential efficacy in hospitalized patients in need of oxygen supplementation up to 60% FiO2, a large proportion of hospitalized COVID-19 patients. The Phase 2/3 study results are also consistent with opaganib's earlier U.S Phase 2 study results and the demonstrated potent antiviral inhibition of SARS-CoV-2 variants in human bronchial epithelial cells, providing further support for its potential in earlier stages of disease where viral load is higher.

Additional new preclinical results demonstrating opaganib's efficacy in significantly decreasing renal fibrosis in a unilateral ureteral obstruction-induced renal interstitial fibrosis mode were also reported by the Company in September 2021.

The Company has submitted data packages for opaganib to the regulatory agencies in the U.S., EU, UK and other territories, ahead of planned regulatory advice, with the European Medicines Agency (EMA) having provided expedited evaluation process timelines. As previously stated, additional studies to support the potential of such applications and the use or marketing of opaganib are likely to be required. For example, the FDA has previously indicated that we will need to complete additional studies to support applications in the U.S. The strength of the safety and efficacy data generated from the opaganib studies will be key to regulatory applications.

The Company also continues its discussions with U.S. and other government agencies and non-governmental organizations around potential funding to support the ongoing development of opaganib. Discussions are also ongoing with potential partners who are interested in the rights to opaganib in various territories.

COVID-19 Program: RHB-107 (upamostat)[8]
RedHill continues to advance the Phase 2/3 study of novel, once-daily, orally-administered, antiviral drug candidate, RHB-107, in the treatment of non-hospitalized patients with symptomatic COVID-19 in the early course of the disease who do not require supplemental oxygen - the vast majority of COVID-19 patients. The study plans to test for the Omicron variant.

Further to announcing in September 2021 that South Africa had joined the U.S. in approving the Phase 2/3 study, along with the expansion to additional U.S. sites, the Company announced this month that the last patient had been enrolled in Part A of the Phase 2/3 study. The study is a 2-part trial designed to evaluate time to sustained recovery from illness as the primary endpoint and for dose selection. A total of 61 patients have been enrolled in Part A and based on safety and tolerability results of part A, a dose for part B will be selected. Top-line results from Part A of the study are expected in the first quarter of 2022, with Part B of the study expected to follow subsequent to discussions with regulators.

RHB-204 - Pulmonary Nontuberculous Mycobacteria (NTM) Disease  
A U.S. Phase 3 study is ongoing to evaluate the efficacy and safety of RHB-204 in adults with pulmonary NTM disease caused by  Mycobacterium avium  Complex (MAC) infection. The Company is also assessing potential expansion of the RHB-204 Phase 3 study to additional territories.

The Company previously announced that the FDA granted Fast Track designation for RHB-204, providing early and frequent communications and a rolling review of any New Drug Application (NDA). RHB-204 is also eligible for NDA Priority Review and Accelerated Approval.

RHB-204 was granted FDA Orphan Drug designation and Qualified Infectious Disease Product designation, extending its U.S. market exclusivity to a potential total of 12 years upon potential FDA approval.

RHB-104 - Crohn's Disease  
Based on recent published research, potential progress in Mycobacterium avium subspecies paratuberculosis (MAP) diagnostic technology may enable us to advance the program towards a confirmatory study in approximately 150 MAP positive moderate-severe Crohn's patients, subject to required regulatory input.

Opaganib - Prostate Cancer and Cholangiocarcinoma
In August 2021, we announced that, based on a preliminary review of partial and unaudited data, the ongoing Phase 2 study for prostate cancer had met its primary endpoint of at least six subjects demonstrating disease control (defined as stable disease or better after 16 weeks on treatment) among at least 27 evaluable subjects. Upon further review and analysis of the unaudited data, the Company reported that the study did not meet its primary endpoint in the study arm evaluating opaganib in combination with enzalutamide. Patient enrolment continues for the study's other arm, evaluating a combination of opaganib and abiraterone. Accrual and data entry are ongoing and results for the study remain subject to further review and analysis.

The Phase 2a study evaluating the activity of opaganib in advanced cholangiocarcinoma (bile duct cancer) is ongoing at Mayo Clinics in Arizona and Minnesota, Emory University and the Huntsman Cancer Institute at the University of Utah. Enrollment has been completed for the first cohort of 39 patients, evaluating the activity of orally-administered opaganib as a stand-alone treatment. Preliminary data from this cohort indicated a signal of activity in a number of subjects with advanced cholangiocarcinoma. Enrollment is ongoing for a second cohort, evaluating opaganib in combination with hydroxychloroquine, an anti-autophagy agent.

Conference Call and Webcast Information:

The Company will host a webcast today, Tuesday, November 30, 2021, at 8:30 a.m. EST, during which it will present key highlights for the third quarter of 2021.

The webcast including slides will be broadcast live on the Company's website, https://ir.redhillbio.com/events, and will be available for replay for 30 days.                          

To participate in the conference call, please dial one of the following numbers 15 minutes prior to the start of the call: United States: +1-877-870-9135; International: +1-646-741-3167 and Israel:
+972-3-530-8845; the access code for the call is: 9753927.

About RedHill Biopharma  
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs, Movantik ® for opioid-induced constipation in adults, Talicia ®  for the treatment of Helicobacter pylori (H. pylori) infection in adults, and Aemcolo ® for the treatment of travelers' diarrhea in adults. RedHill's key clinical late-stage development programs include: (i) RHB-204,  with an ongoing Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) disease; (ii) opaganib ( ABC294640), a first-in-class, oral SK2 selective inhibitor targeting multiple indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (iii) RHB-107 (upamostat), an oral serine protease inhibitor in a U.S. Phase 2/3 study as treatment for symptomatic COVID-19, and targeting multiple other cancer and inflammatory gastrointestinal diseases; (iv) RHB-104, with positive results from a first Phase 3 study for Crohn's disease; (v) RHB-102, with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; and (vi) RHB-106, an encapsulated bowel preparation. More information about the Company is available at www.redhillbio.com / https://twitter.com/RedHillBio.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements include statements regarding the timing of top-line results of Part A of the Phase 2/3 study of once-daily oral RHB-107 in non-hospitalized patients with symptomatic COVID-19. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the risk of a delay in top-line data from Part A of the Phase 2/3 study of once-daily oral RHB-107 in non-hospitalized patients with symptomatic COVID-19, that the Phase 2/3 COVID-19 study for RHB-107 may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional COVID-19 studies for opaganib and RHB-107 are likely to be required, as well as risks and uncertainties associated with the risk that the Company will not successfully commercialize its products; as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company's research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of a commercial companion diagnostic for the detection of MAP; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company's therapeutic candidates and Talicia ®; (v) the Company's ability to successfully commercialize and promote Talicia ®, and Aemcolo ® and Movantik ®; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company's therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (ix) the implementation of the Company's business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company's expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company's Expanded Access Program; (xiv) competition from other companies and technologies within the Company's industry; and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on March 18, 2021. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.

 

Company contact:

Adi Frish

Chief Corporate and Business Development Officer

RedHill Biopharma

+972-54-6543-112

adi@redhillbio.com

 

Media contacts:

U.S.: Bryan Gibbs, Finn Partners

+1 212 529 2236

bryan.gibbs@finnpartners.com

UK: Amber Fennell, Consilium

+44 (0) 7739 658 783  

fennell@consilium-comms.com

 

REDHILL BIOPHARMA LTD.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited)












Three Months Ended


Nine Months Ended



September  30,  


September  30,  



2021


2020


2021


2020



U.S.  dollars  in  thousands

NET REVENUES


21,609


20,943


63,686


42,898

COST OF REVENUES


9,229


10,337


30,072


26,240

GROSS PROFIT


12,380


10,606


33,614


16,658

RESEARCH AND DEVELOPMENT EXPENSES


5,818


4,323


23,630


10,302

SELLING AND MARKETING EXPENSES


15,525


13,414


44,655


32,384

GENERAL AND ADMINISTRATIVE EXPENSES


8,435


7,329


25,765


17,948

OPERATING LOSS


17,398


14,460


60,436


43,976

FINANCIAL INCOME


17


42


39


339

FINANCIAL EXPENSES


4,006


4,220


12,974


8,205

FINANCIAL EXPENSES, net


3,989


4,178


12,935


7,866

LOSS AND COMPREHENSIVE LOSS FOR THE PERIOD


21,387


18,638


73,371


51,842










LOSS PER ORDINARY SHARE, basic and diluted  (U.S. dollars):


0.05


0.05


0.16


0.14

WEIGHTED AVERAGE OF ORDINARY SHARES (in thousands)


467,908


372,893


454,995


359,428

 

 

REDHILL BIOPHARMA LTD.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION













September  30,  


December  31,  



2021


2020



 U.S.  dollars  in  thousands

CURRENT ASSETS:





Cash and cash equivalents


23,254


29,295

Bank deposits


12,028


17

Financial assets at fair value through profit or loss


—


481

Trade receivables


30,036


28,655

Prepaid expenses and other receivables


4,682


5,521

Inventory


13,115


6,526



83,115


70,495

NON-CURRENT ASSETS:





Restricted cash


16,163


16,164

Fixed assets


477


511

Right-of-use assets


4,193


5,192

Intangible assets


82,388


87,879



103,221


109,746

TOTAL ASSETS


186,336


180,241











CURRENT LIABILITIES:  





Account payable


15,245


11,553

Lease liabilities


1,743


1,710

Allowance for deductions from revenue


28,356


18,343

Accrued expenses and other current liabilities


20,587


24,082

Payable in respect of intangible assets purchase


15,731


17,547



81,662


73,235






NON-CURRENT LIABILITIES:





Borrowing


83,516


81,386

Payable in respect of intangible assets purchase


6,010


7,199

Lease liabilities


2,849


3,807

Royalty obligation


750


750



93,125


93,142

TOTAL LIABILITIES


174,787


166,377






EQUITY:





Ordinary shares


1,316


1,054

Additional paid-in capital


355,601


293,144

Accumulated deficit


(345,368)


(280,334)

TOTAL EQUITY


11,549


13,864

TOTAL LIABILITIES AND EQUITY


186,336


180,241

 

 

REDHILL BIOPHARMA LTD.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
(Unaudited)












Three Months Ended


Nine Months Ended



September  30,  


September  30,  



2021


2020


2021


2020



U.S.  dollars  in  thousands

OPERATING ACTIVITIES:









Comprehensive loss


(21,387)


(18,638)


(73,371)


(51,842)

Adjustments in respect of income and expenses not involving cash flow:









Share-based compensation to employees and service providers


2,191


1,695


8,337


3,120

Depreciation


507


470


1,465


1,237

Amortization and impairment of intangible assets


1,834


2,109


5,491


4,958

Non-cash interest expenses related to borrowing and payable in respect of intangible assets purchase


869


2,039


4,725


3,656

Fair value losses on financial assets at fair value through profit or loss


—


31


6


68

Exchange differences and revaluation of bank deposits


17


5


80


(160)



5,418


6,349


20,104


12,879

Changes in assets and liability items:









Decrease (increase) in trade receivables


62


6,146


(1,381)


(11,208)

Decrease (increase) in prepaid expenses and other receivables


(390)


235


839


(2,391)

Increase in inventories


(4,352)


(350)


(6,589)


(3,218)

Increase in accounts payable


1,939


1,261


3,692


2,385

Increase (decrease) in accrued expenses and other liabilities


(2,575)


(4,687)


(3,495)


17,437

Increase in allowance for deductions from revenue


2,260


513


10,013


84



(3,056)


3,118


3,079


3,089

Net cash used in operating activities


(19,025)


(9,171)


(50,188)


(35,874)

INVESTING ACTIVITIES:









Purchase of fixed assets


(21)


(166)


(112)


(357)

Purchase of intangible assets


—


(735)


—


(53,368)

Change in investment in current bank deposits


(8,500)


—


(12,000)


4,200

Proceeds from sale of financial assets at fair value through profit or loss


—


2,075


475


6,025

Net cash provided by (used in) investing activities


(8,521)


1,174


(11,637)


(43,500)

FINANCING ACTIVITIES:









Proceeds from long-term borrowings, net of transaction costs


—


(784)


—


78,061

Proceeds from issuance of ordinary shares, net of issuance costs


499


9,137


58,713


15,500

Exercise of options into ordinary shares


665


53


4,006


53

Repayment of payable in respect of intangible asset purchase


(1,721)


—


(5,600)


—

Increase in restricted cash


—


—


—


(20,000)

Decrease in restricted cash


—


4,000


—


4,000

Payment of principal with respect to lease liabilities


(442)


(450)


(1,229)


(1,186)

Net cash provided by (used in) financing activities


(999)


11,956


55,890


76,428

 INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS


(28,545)


3,959


(5,936)


(2,946)

EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS


(17)


(33)


(105)


121

BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD


51,816


22,272


29,295


29,023

BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD


23,254


26,198


23,254


26,198

SUPPLEMENTARY INFORMATION ON INTEREST RECEIVED IN CASH


11


71


36


320

SUPPLEMENTARY INFORMATION ON INTEREST PAID IN CASH


3,250


2,147


8,266


4,507

SUPPLEMENTARY INFORMATION ON NON-CASH INVESTING AND FINANCING ACTIVITIES:









Acquisition of right-of-use assets by means of lease liabilities


385


533


385


2,738

Purchase of intangible assets posted as payable


—


12,511


—


24,619

Purchase of an intangible asset in consideration for issuance of shares


—


1,914


—


1,914

 

[1] Including cash, cash equivalents, bank deposits and restricted cash
[2] John M. Aitken, Khoi Phan, Samantha E. Bodman, Sowmya Sharma, Anthony Watt, Peter M. George, Gaurav Agrawal, Andrew B.M. Tie: A Mycobacterium species for Crohn's disease? Pathology, 2021 Dec;53(7):818-823
[3] All financial highlights are approximate and are rounded to the nearest hundreds of thousands.
[4] Movantik ® (naloxegol) is indicated for opioid-induced constipation (OIC). Full prescribing information see: www.movantik.com.
[5] Talicia ® (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of H. pylori infection in adults. For full prescribing information see: www.Talicia.com.
[6] Aemcolo ® (rifamycin) is indicated for the treatment of travelers' diarrhea caused by noninvasive strains of Escherichia coli in adults. For full prescribing information see: www.aemcolo.com  
[7] Opaganib (ABC294640, Yeliva ®) is an investigational new drug, not available for commercial distribution.
[8] RHB-107 (upamostat) is an investigational new drug, not available for commercial distribution.

Logo - https://mma.prnewswire.com/media/1334141/RedHill_Biopharma_Logo.jpg

 

More News by PR Newswire India

Straive's Intelligent Document Processing (IDP) capabilities featured in ISG's Provider Lens™ Intelligent Automation -- Solutions & Services US Report 2021

Star Air Celebrates 3 years of Connecting Real India

Indian Marketers Rank Mobile and Social Media as Top Priorities for 2022 but Ad Fraud Remains a Huge Challenge, Integral Ad Science study finds

Turing Launches a Global, Career-Centric Community for Developers

Sungrow Ranks First in 2021 China Top 500 ESG Companies

CCTV+: Xi sends congratulatory letter to CMG Forum

CGTN: Xi sends congratulatory letter to CMG Forum

iMediSync Successfully Launches the Future of Tele-Medicare at CES 2022

Asia facing 'triple policy challenge' to long-term growth, new Asia House report finds

Skybox Security expands market leadership with over 4x growth in subscription business from new customers in 2021

GWM POER Gains Global Recognition for Its Outstanding Performance

Rafay Systems Announces Streamlined Operations for Virtual Machine-Based Applications on Kubernetes

EDM Council Publishes Study for Managing Challenges of ESG Data For Rating Providers and Data Aggregators

Bill & Melinda Gates Foundation Appoints Board of Trustees - Four New Members Join Co-Chairs Bill Gates and Melinda French Gates to Shape Foundation Governance and Increase Impact

SOPHiA GENETICS Appoints Ken Freedman as Chief Revenue Officer

Only Continuous Transformation Cultures Will Survive

Cisco Study Finds Privacy is Now Mission Critical for Organizations Worldwide

HUGO BOSS RELEASES STAR-STUDDED CAMPAIGNS FOR BOSS AND HUGO AS PART OF ITS COMPREHENSIVE BRAND REFRESH

Global Infrastructure Partners Announces The Election of Three New Partners

Altair PollEx for Altium, First in Series, Launched for Printed Circuit Board Design

Clarivate Launches New Global Research Report on Managing Academic Publication Credit in a Collaborative World

HotForex Granted License by the Capital Markets Authority (CMA) of Kenya

Top 10 Growth Opportunities in Energy & Environment Industry to Enhance Company Profitability

Launch of the THOMAS SABO Ocean Vibes Collection Spring/Summer 2022

Hisense Commits to Achieve GHG Emissions Reduction Target: A 202.6% Reduction from 2021 Levels by 2022

The Belvedere Museum in Vienna Sells NFTs of The Kiss by Gustav Klimt for Valentine's Day

TCS Wins the Frost & Sullivan Technology Innovation Award

Infosys Named the Fastest-Growing IT Services Brand in the World; Among Top 25 Fastest-Growing Brands across Sectors Globally

XREX Acquires Money Services Business License from Canada's FINTRAC

"CULTURE GATE to JAPAN"

CGTN: 30 years on, China to build closer community of shared future with Central Asian nations

Asia Alternatives Announces Fund Closings of US$2 billion

Genesis Systems, leading U.S. sustainable water technology start-up, breaks fundraising records with early round led by X-PRIZE's Global Water Prize Co-founder.

Shield AI Establishes International Office in UAE under Leadership of Bob Harward

New agreement between Saudi Ministry of Culture and Cirque du Soleil Entertainment Group opens door for major new productions in the Kingdom

CLASE AZUL UNVEILS NEW BRAND IDENTITY

Acceldata Adds Sanjay Poonen, Former SAP President and VMWare COO, as an Advisor and Investor

How Blue United is Disrupting Healthcare Through Blockchain Technology

PT. Mowilex Indonesia Applauded by Frost & Sullivan for Addressing Supply Chain Volatility Issues and Promoting Environmental Sustainability with Its Novel Eco-Friendly Products

3Pillar Global's India Workplace Culture Acknowledged by Great Place to Work® Institute For The Fifth Year In A Row

NetNumber Expands 5G Capabilities for Private Networks

Aon: $343 Billion in Global Weather-, Catastrophe-Related Economic Losses Reported in 2021, Up From $297 Billion in 2020

Radancy Announces Acquisition of Firstbird - A Global Leader in SaaS Based Employee Referral Programs

Frost & Sullivan Recognizes Startek® with Americas New Product Innovation Award

Frost & Sullivan recognizes Colt Technology Services as the Customer Value Leader in the European Managed SD WAN Services Industry

Bitmain-Backed BitFuFu (Finfront Holding Company), a World-Leading Digital Assets Cloud Mining Service Provider, Entered into a Definitive Merger Agreement with Arisz Acquisition Corp.

Renowned Asian Oral Care Brand usmile Reveals Flagship Powered Toothbrush Globally

Gastops Expands ChipCHECK Engine Coverage with Alloy Library Update

DIGITAL SAT BRINGS STUDENT-FRIENDLY CHANGES TO TEST EXPERIENCE

Technology Finance leader joins to drive innovation as Practus transforms the finance advisory space

Amp Energy announces the largest battery storage facilities in Europe with two flagship 400 MW projects located in Scotland

Chandigarh University ranks among the Top Universities of India in the field of Research and Innovation

STL wins INR ~170 crore deal for building a Unified Network Management System for PGCIL

Rupifi onboards Koovs Founder to head B2B Payments Innovation and Product Expansion

Acuité Ratings & Research Limited Is Now Great Place to Work-Certified™

CHEP once again recognised among India's Top Employers 2022

Dr Jane Goodall delivers an important message of hope at the 2022 Procter & Gamble AMA Sustainability Summit

Dataloop Applauded by Frost & Sullivan for Accelerating Computer Vision AI Model Production with its Data Management and Annotation Platform

Edufront and Ashraya Support Mijwan Welfare Society's Efforts to Empower Girl Child Students

Asia's leading HR technology platform Darwinbox raises $72 Million funding led by Technology Crossover Ventures (TCV) at $1B+ valuation

Skybox Security announces 2021 Partner of the Year Award winners

Lifebit partners with NIHR Cambridge Biomedical Research Centre to launch the CYNAPSE platform for next-generation genomics research

Deepak Nitrite Limited Announces Q3 & 9M FY2022 Earnings

Elixia Tech Solutions Launches Elixia Connect

Deliverect Raises $150 Million in Series D Funding, as it Reaches 100 Million Orders Processed

Havas Group acquires Paris-based MedEd specialist Raison de Santé to Reinforce its Global Medical Education Offering within Havas Health & You

GWM's New Category HAVAL DARGO is Entering the Global Market

Blue Nectar launches authentic Kumkumadi Tailam with a brand-new skin care range of pure Ayurvedic products

Hipi's virtual singing talent hunt - Hipi G.O.A.T. contest receives jaw dropping participation: Over 25000 videos in just the first 2 rounds

Tech Startup Aerion Labs premieres world's first head-mounted air purifier in India

CGI is now Great Place to Work - Certified™ in India

Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform

ideaForge completes in time delivery of the $20m SWITCH 1.0 UAVs contract and starts work on additional order

HarperCollins Publishers India presents Turds of Gold by Jugal Mody

Kissflow announces $1 million giveaway for SaaS communities

Tredence Propels Intelligent Enterprise Rebate Management with Launch of Rebate.ai

Pan India D2C Coffee brand SLAY Coffee announces strategic tie-up with Farmer Produce Organisation for coffee sourcing

AFS expands program to catalyze 5,000 young changemakers worldwide

Sarine Diamond Journey(TM) Traceability and AI-Driven Grading Adopted by High Jewellery Maison Boucheron

STOCK TRADER WINS U.S. INVESTING CHAMPIONSHIP A SECOND TIME - BREAKS RECORD

IMPRESSION Randomized Trial: Past the halfway mark and progressing rapidly

Siklu and Signify Announce Agreement to Integrate Gigabit-Speed Wireless Connectivity into Lighting Infrastructure

Angie Frederick joins C5MI as Partner and Chief Operating Officer

The INX Digital Company, Inc. Announces Public Listing on NEO Exchange; Trading Begins Today Under Symbol "INXD"

Rogers International Commodity Index (RICI®) Composition Unchanged

The Green Coffee Company Funds $13.2 million Series B Round to bring total equity invested to $25 million; On Path to Becoming Colombia's #1 Largest Coffee Producer

India's first and largest self-storage company is all set to soar in 2022

International Day of Education 2022: Zoomlion's Onsite Engineering Certificate Program Promotes Future Industry 4.0 Talent

'postpe' dominates BNPL market: Clocks annualized TPV of Rs. 2,400 crores in 3 months of launch

Cendyn and Pegasus complete merger

MedPiper Announces Hackemist - A One-Of-A-Kind Hackathon Targeted Towards Healthcare Innovation

Share India Securities Q3FY22 Results: PAT grows to Rs 48.8 crores; revenue, income figures witness outstanding upward trajectory

GLOBAL FINTECH BANK TAKES OFF

RateGain's latest RGLabs Innovation selected by US Car Rental company Malco Enterprises to Accelerate Revenue Recovery

Heritage Foods' consolidated Q3 FY2022 revenue grows by 10.3% YoY at INR 6,670 million

Geek RoboCook's new brand campaign talks about reducing kitchen time and spend more time with friends/family

Applied Pharmaceutical Science Inc. Announces FDA Approval of Investigational New Drug Application for APS03118, a Next generation RET Original New Drug for Unlimited Cancers

Huobi Launches $100 Million Lunar New Year Campaign to Support Metaverse Development

Azentio Software announces Aliza Knox as new Board Member

Heidrick & Struggles Appoints New Leaders for Asia Pacific & Middle East

CGTN: How is Tonga coping after being battered by a volcanic eruption and ensuing tsunami?

Rela Hospital saves the life of a Two-and-a-half-year-Old Child by successfully performing a rare ECMO CPR Procedure

Voltas & Voltas Beko launch their exclusive, one of its kind, Experience Zone at Prabhadevi, in Mumbai

FlowerAura Celebrates A Heart-To-Heart Relationship With Its Valentine Day Gifts

Pearl Academy announces scholarships for creative and business minds

CGTN exclusive interview with Chinese businessman in Tonga

BUDDHIST LEADER AND "FATHER OF MINDFULNESS," THICH NHAT HANH PASSES AWAY

Swiss Pharma Company - IDEOGEN takes over Special Access Program for BELEODAQ® (belinostat)

SHL wins eleven Industry Awards across Asia: SHL's Cutting edge solutions won the Highest Category Awards throughout 2021

Nagarro joins forces with Techmill Global

Applitools Wins Best Testing Service and Tool in DevOps Dozen 2021 Awards

POKERSTARS AND RED BULL RACING SEAL GLOBAL PARTNERSHIP

If You Purchased or Acquired CTR Tokens, You may be Eligible to Receive Money From Forfeited Assets

GMT partner up with Simplex to allow to buy token with credit card

ARMANI BEAUTY ANNOUNCING TESSA THOMPSON AS THE NEWEST BEAUTY FACE

Trina Solar Chairman Gao Jifan: Better solar, better world

XCMG Delivers New XC9 Loaders to Israel, Thailand and Countries in Europe, as Cumulative Loader Export Mounts 100,000 Units

CELEBRATE LUNAR NEW YEAR WITH JOHNNIE WALKER BLUE LABEL

Vignan (Deemed-to-be-University) forays into ed-tech space; launches Vignan Online

Ashraya Foundation Signs 60 Crore INR Agreement with Edufront Technologies

T-Systems Names Anant Padmanabhan as Managing Director

Priority sector lending can help unlock EV financing market of INR 40,000 crore by 2025 and achieve the COP26 targets

CGTN Exclusive: A Chinese employee currently working in Tonga described

CGI supports Karnataka Government to strengthen their COVID Care Centre in Bengaluru

Zentiva awarded Top Employer accolade

Hisense Announced 2021 Full-Year Result, Revenue Hit Historical High of US$27.2 Billion

ABB India turns its Nelamangala Campus 'water positive'

Madhavbaug's book 'Live without Diabetes' launched by Hon. Finance Minister (State) Dr. Bhagwat Karad

BYJU'S And The Akshaya Patra Foundation Join Forces To Support Education Of Underprivileged Students

CGI is recognized as a Top Employer 2022 in India

SecureThings Lauded by Frost & Sullivan for Addressing Connected-vehicle Cybersecurity Challenges through Continuous Vehicle Monitoring

GradRight and Prodigy Finance come together to support Rohit's dream of international higher education

Guild Esports Signs Exclusive ÂŁ4.5m Sponsorship Deal with Bitstamp

Shell completes sale of interest in Deer Park refinery to partner Pemex

2022 GAC MOTOR International Distributor Conference

DAPPER LABS AND UFC LAUNCH 'UFC STRIKE': AN ALL NEW NFT EXPERIENCE FOR MMA FANS EVERYWHERE

Nozomi Networks Awarded by Frost & Sullivan for Leading the Operational Technology and IoT Cybersecurity Industry with Superior and Highly Differentiated Solutions

QB LAUNCHES LIQUIDITY TRACKING TOOL FOR REAL-TIME ANALYSIS TO HELP ACHIEVE BEST EXECUTION

Bridget Johnson Joins CSafe Global as Senior Vice President of Marketing

Leading Capital Markets Protocol Folks Finance Closes $3 Million Seed Funding Round

Yutong Bus Shows Steady Growth with Expected Net Profit to Grow US$7.87 Million to $23.61 Million for 2021, A 10% to 30% YoY Increase

Victor Papamoniodis Joins Medison Pharma as VP International Markets

Armaan Malik's latest track 'You' breaks all records on Moj; crosses 2 billion views in 5 days

Sputnik V demonstrates strong protection against Omicron variant, with over 2 times higher virus neutralizing activity compared to the Pfizer vaccine according to a unique independent comparative study conducted by the Spallanzani Institute in Italy

HarperCollins Publishers India announces the publication of 'It's Your Baby' by Dr Saroja Balan

Infosys Recognized as Global Top Employer for the Second Consecutive Year; Ranked #1 in India Again

Arctech Expands Global Footprint: Shine Forward in 2022

Arçelik Recognised in the Corporate Knights' 2022 Global 100 Index

HarperCollins Publishers India is proud to announce 'The Great Tech Game- Shaping Geopolitics and the Destinies of Nations' by Anirudh Suri

Colliers ropes in three senior experts to further strengthen its service capabilities in Mumbai

beGalileo, the Mathematical Thinking & Cognitive Capability Building Program signs up Sania Mirza as Brand Ambassador

zunpulse (ZunRoof Tech Private Limited) wins the National Startup award 2021 by Startup India in the Energy Sector

Airbiquity Strengthens Collaboration with Renesas for Continued Technology Integration Efforts

Successful Completion of First Patient Implantation of MINI WELL® and MINI WELL TORIC® Extended Depth-of-Focus IOLs in China Announced by Affamed Technologies, Joint Venture between AffaMed Therapeutics and SIFI

Schneider Electric Introduces Infrastructure of the Future

JTI recognized among the elite of Global Top Employers for its innovative approach to equality and wellbeing

CIE-IIITH's Start up Demo Day sees 15 startups pitched to 35 angels, VCs & corporates

Glenmark Specialty S.A. and Lotus International Pte. Ltd. enter into Exclusive Licensing Agreement for commercializing Ryaltris™ Nasal Spray in Singapore, Hong Kong and Vietnam

Artha to represent Talend in India as Master VAR

Iconic M&M'S® Brand Announces Global Commitment to Creating A World Where Everyone Feels They Belong

Kirloskar Brothers Limited wins 'India's Most Ethical Company' Award

VVDN opens 5G Test Lab to provide ORAN, RCT and Inter-Operability Testing Services

HarperCollins presents 'Twelfth Fail: Hara Vahi Jo Lada Nahi' By Anurag Pathak, Translated by Gautam Choubey and Lalit Kumar

Tejas Networks Appoints Mr. N. Ganapathy Subramaniam and Mr. Amur S. Lakshminarayanan as Directors

Dover Corporation continues its scale up of Altizon's Datonis Digital Factory

Daffodil Software Announces Expansion Plans, To Hire 500 Employees this Year

Emerson Introduces World's First Non-Contacting Radar Level Transmitter Designed Specifically for Food and Beverage Applications

Canadian Soprano Measha Brueggergosman-Lee launches The Measha Series: A 4-part Exploration of Jazz, Classical Song, Gospel and Dance virtually showcasing a Roster of Nova Scotia's Hidden Musical Talents… and Margaret Atwood

Hikvision becomes the Official Sponsor of the Hangzhou 2022 Asian Games

"JEWISH NOBEL" AWARDED TO PFIZER CEO ALBERT BOURLA

Artmarket.com: For a classification of NFTs on marketplaces and in Artprice databases

Cloud-based solutions provider Eka completes record 16 product implementations in 2021

LTI constant currency revenues grow 9.2% QoQ and 30.1% YoY; Net profit up by 18.0% YoY

MAYBELLINE NEW YORK INTRODUCES ITS CONSCIOUS TOGETHER PROGRAM

Enterprises Adopting Intelligent Service Management Tools to Improve Employee Satisfaction

Operation Smile Announces 10-Year Commitment to Transform the Lives of 1 Million Patients Globally

CoinPayments Appoints Kalin Kalinov as Chief Marketing Officer to Lead Global Marketing Operations

Iridium Supports Reactivated Monuments Officers

STL poised for growth; declares solid wins in new markets and accelerates investments in 5G

Volvo recognized as one of the Best Brands in 2021 by Economic Times

Ground Labs launches Data Discovery Network helping partners to solve growing compliance requirements while boosting recurring revenue streams

Octapharma puts a spotlight on the challenges of managing inhibitors in haemophilia A at the 15th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

MediaTek Shows The World's First Live Demos of Wi-Fi 7 Technology to Customers and Industry Leaders

US-based software company MindBowser Redefines Work Culture with MindBowser Mileage (M2) Programme

Accomplished Pharma R&D leader, Sauri Gudlavalleti joins Sai Life Sciences as Chief Operating Officer

THE SLEEP COMPANY KICKS OF 2022 WITH A BANG! LAUNCHES ITS STATE-OF-THE-ART, ZERO-GRAVITY 'ELEV8 SMART ADJUSTABLE BED' & 'SMART ORTHO HYBRID MATTRESS'

Smart City Living Lab at IIITH Announces Winners of Water Challenge

Cricket NFT platform Rario announces partnership with star studded Legends League Cricket

Xinhua Silk Road: Haier Group aims high in sci-tech innovation to embrace bright future in digital age

Sean Tao, partner of EVG, speaks at the Forbes U30 Summit China Explores community value and adaption of the Metaverse

LEXUS INDIA OPENS PRE-BOOKINGS FOR THE ALL-NEW LEXUS NX 350h

PayU launches full-stack solutions; helps SMBs access credit starting from Rs. 25,000

Shanghai Electric Launches Chinese Language Training Program for Pakistan's Personnel on Thar Block-1 Integrated Coal Mine and Power Project

COVIDROPS™ and COVINHALER® - Indian startups rooting for Nasal sprays and Pocket Inhalers for COVID-19 therapeutics

Apis Growth Fund II invests US$50 million Series C in Giift, a Global Leader in Loyalty Program Management

Sims Limited Included on the Global 100 List of the World's Most Sustainable Companies

Star Localmart enters Pune, Plans to launch 100 stores in FY23

Patent Awarded to Nanoprecise Sci Corp for its Automated Predictive Maintenance Solution

HarperCollins Presents Teething: A Story Told in Verse By Megha Rao

20% of Maharashtra's Best Educators teach at JBCN Oshiwara

Everest Group Names Pennant Technologies as a Major Contender in Consumer Loan Origination Systems PEAK Matrix® Assessment 2022

Good news to patients with corneal blindness: MIOK Keratoprosthesis, the World's First Artificial Cornea of 100% Non-biological Materials has been approved for listing in China.

HarperCollins Publishers India is delighted to announce The Blue Book: A Writer's Journal by Amitava Kumar

Heifer International, Cargill and Walmart Foundation Partner to Invest in Farmer Producer Organizations in India

Lotus Eye Hospital and Institute reveals their message for 2022: See The World Better

XtalPi Partners with Excelra for GOSTAR to Enhance its Intelligent Digital Drug Discovery and Development platform

Sensormatic Solutions by Johnson Controls prioritizes responsible retail by continued focus and investment into sustainability practices

Transplant Connect to Expand Human Biologics Management Software with Investment from InVita Healthcare Technologies

Rockwell Automation Wins "Industrial IoT Solution of the Year" Award in 6th Annual IoT Breakthrough Awards Program

Bill & Melinda Gates Foundation and Wellcome Pledge US$300 Million to CEPI for COVID-19 Pandemic Response and to Accelerate Epidemic Preparedness

Burns & McDonnell India Announces New Leadership

REALTY ONE GROUP AGAIN NAMED REAL ESTATE'S ONLY FAST & SERIOUS FRANCHISOR ON FRANCHISE TIMES LIST

DARKTRACE SIGNS MULTI-MILLION-DOLLAR DEAL WITH TOP GLOBAL AIRLINE

$18.6 BILLION IN BUSINESS FOR BNI® MEMBERS WORLDWIDE PROVES THE POWER OF WORD-OF-MOUTH NETWORKING

Gartner Mentions FarEye in the 2021 Market Guide for Vehicle Routing & Scheduling and Last Mile Technologies for the Fourth Time in a Row

Solace Announces Latest Advances in Event Horizon Initiative, including Expansion of EDA Summit Program

CliniSys acquires HORIZON Lab Systems and combines with Sunquest Information Systems to create one of the world's largest organizations dedicated to diagnostics and laboratory informatics

Microsoft to acquire Activision Blizzard to bring the joy and community of gaming to everyone, across every device

Bigtincan is a Gold Medalist in the 2022 SoftwareReviews Sales Enablement Data Quadrant Buyers Guide Report

Nobu Hospitality to Launch a Hotel and Restaurant on the Stunning Island of Santorini, Greece

LigoLab Applauded by Frost & Sullivan for Transforming Diagnostic Laboratories with its All-in-One Integrated LIS & RCM Platform

Frost & Sullivan Applauds AT&T for its Effective Strategy and Competitive Differentiation in the European Managed SD-WAN Services Industry

Frost & Sullivan Recognizes AT&T with the 2021 North American Managed SD-WAN Services Market Leadership Award

Stamus Networks Announces Availability of Suricata Language Server

Sungrow Launches "1+X" Modular Inverter at World Future Energy Summit, 2022

Intersec 5G-ready geolocation platform accelerates positioning use case enablement

Servier Group Reports Financial Year 2020/2021 Annual Results, R&D Strategy and Pipeline

Clarivate Patent Trend Report Shows Increasing Business Focus on Innovation Through Patent Portfolio Spend

Firmenich signs Strategic Partnership Agreement with HARMAY in China

EPS Global and DriveNets Announce Strategic Partnership to Speed the Adoption of Cloud-Native Networking by Leading Operators Worldwide

Dermaliq Therapeutics Signs USD 15 Million Series A Round to Advance Three Transformative Drug Therapies into Clinical Trials

GOVO introduces GOBUDS, GOBASS and GOKIXX series in India

CATL Launches Battery Swap Solution EVOGO Featuring Modular Battery Swapping

HSIL transforms to a focused Packaging Company with the Divestment of Building Products Division for a Cash Consideration of Rs 630 Crore

Rashid Khan, Ruturaj Gaikwad and Prithvi Shaw announce NFT deals with Rario

oneZero Continues to Bolster Institutional Team With Key Hires

Good news for kung fu enthusiasts around the world - Shaolin Temple launches kung fu online games

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Former Congress Uttarakhand chief Kishor...
Those who yearn to equate Uttar Pradesh'...
9 people injured in building collapse in...
Uttarakhand Polls: Congress changes Hari...
BJP, Bajrang Dal protest 'renaming' of s...
Rahul Gandhi meets Jharkhand leaders aft...
More...    
 
 Top Stories
International alliance of MPs calls... 
UP Polls: Rajnath Singh to campaign... 
No chance of reduction in inflation... 
Claire Danes to join Jesse Eisenber... 
Equity indices open in red, Sensex ... 
Japan steps up anti-COVID measures ... 
Powell vindicated his selection, gr... 
Red Velvet JOY unveils photos for C...